Neil Bhowmick, Chief Scientific Officer at Kairos Pharma, explores the biology of cancer drug resistance and the opportunities to overcome it. Despite extraordinary advancements in how we treat cancer, ranging from cytotoxic chemotherapy to precision immunotherapies, one fundamental barrier consistently impedes… Read More
New research has uncovered how treatment-resistant cancer cells may drive poor outcomes for people with triple-negative breast cancer (TNBC). The study, published in Genome Medicine and funded by the charity Breast Cancer Now and others, pinpoints important genes that could be targeted by new drugs. Read More
New research published in the Clinical Lymphoma, Myeloma & Leukemia journal has confirmed that Kappa Myeloma Antigen (KMA) and Lambda Myeloma Antigen (LMA) are promising therapeutic targets for the treatment of multiple myeloma. These antigens are present on malignant plasma cells but… Read More
Researchers have discovered that a subtle chemical change to protein p21 acts as a master regulator of cell division – a finding that could influence future cancer therapies. The study was launched at the Biotechnology Center (BIOTEC) of TUD Dresden University of Technology in Germany and later… Read More
New molecular insights into cancer stem cells have highlighted their potential as therapeutic targets. In a recent study, researchers have revealed how transcription factors CDX1 and CDX2 suppress cancer cell stemness by blocking β-catenin’s ability to activate key genes like LGR5. Their findings showed that… Read More
The European Commission has approved Tevimbra (tislelizumab), in combination with gemcitabine and cisplatin, for the first-line treatment of adult patients with metastatic or recurrent nasopharyngeal carcinoma (NPC), not amenable to curative surgery or radiotherapy. Nasopharyngeal carcinoma is a rare cancer in which malignant cells form in the nasopharynx, the upper… Read More
Reece Armstrong examines the advances being made in identifying cell surface proteins and what this means for cancer drug discovery. There have been some landmark FDA approvals in recent years – but not everyone has picked up on the significance of its decision to green-light Merus’ lung and pancreatic cancer… Read More
Scientists have developed a tool which helps them better understand cancer’s survival tactics and could eventually lead to new treatments for dozens of cancers. ‘Synthetic lethality’, the tactic of blocking pathways that cancer cells rely on, has so far mainly been successful in patients with BRCA-mutated breast,… Read More
Rappta Therapeutics, a company developing anti-cancer drugs, has entered a global license agreement with SpringWorks Therapeutics for RPT04402, a first-in-class molecular glue of specific protein phosphatase 2A (PP2A) complexes. Rappta’s PP2A-reactivating technologies are developed using high resolution structural data and have the potential to create a new class of anti-cancer… Read More
Kathryn L Chapman, Head of Discovery Biology & Jürgen Moll CSO at Tesselate Bio, explore alternative approaches to synthetic lethality to target cancer cells that use alternative lengthening of telomersin. Synthetic lethality and targeted drugs are a clinically established approach Synthetic lethality (SL) is an established, clinical and commercial approach… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. As we are halfway through Breast Cancer Awareness Month, our news highlights this week… Read More
News round-up for 14-18 October by DDW Senior Digital Content Editor Diana Spencer. As we are halfway through Breast Cancer Awareness Month, our news highlights this week focus on studies that could advance the treatment of cancer in the future, including a new understanding of cancer drug… Read More
New research has detailed each type of cancer mutation that causes drug resistance, helping to uncover targets for drug development and identify potential effective second-line therapies. In a new large-scale study, researchers from the Wellcome Sanger Institute, EMBL’s European Bioinformatics Institute (EMBL-EBI), Open Targets, and collaborators… Read More
Etcembly has launched a new research study aiming to uncover new targets for cancer therapies by analysing the immune cells of cancer survivors. The ETCh study is recruiting people aged 18-65 who are living with or have survived cancer to join the study, as well as… Read More
Scientists have pinpointed thousands of genetic changes in a gene that may increase a person’s risk of developing breast and ovarian cancer and also identified new potential therapeutic targets. Researchers from the Wellcome Sanger Institute and their collaborators focused on the ‘cancer protection’ gene RAD51C, known… Read More
Scientists have discovered that a protein linked to prostate cancer is associated with more aggressive disease and could be a new target for treatment. The team at The Institute of Cancer Research, London, UK, have shown that the BCL2 protein was abundant in a subtype of… Read More
